Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07313462

Escalation vs. Induction Therapy Strategy in Patients With Early-Onset MS After Age 50

The objective of this study is to evaluate the risk of inflammatory disease activity by retrospectively comparing two therapeutic strategies (escalation group and induction group). The investigators also aim to identify factors associated with inflammatory relapse and treatment-related complications.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Multiple Sclerosis (MS) Autoimmune Diseases Autoimmune Diseases of the Nervous System Demyelinating Autoimmune Diseases, CNS Demyelinating Diseases Immune System Diseases Multiple Sclerosis Nervous System Diseases

Age range

50 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Centre d'Investigation Clinique - CHU de Strasbourg - France

Strasbourg, 67091, France

Location status: Recruiting

Location contact

Anne KERBRAT, MD

SUB_INVESTIGATOR

Guillaume JOUVENOT, PhD

PRINCIPAL_INVESTIGATOR

Nicolas Collongues, MD

CONTACT

[email protected]

33 3.88.12.87.33

Nicolas Collongues, MD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with RRMS onset after age 50
  • Patients who started their first disease-modifying therapy within 2 years of the first symptoms
  • Patients Treated with moderately effective disease-modifying antirheumatic drugs (DMARDs) (teriflunomide, dimethyl fumarate or diroximel fumarate, glatiramer acetate, interferon beta, peginterferon)
  • Patient treated with highly effective DMARDs (fingolimod, ponesimod, natalizumab, rituximab, ocrelizumab, ofatumumab, cladribine)

Exclusion criteria

  • Patients with early progressive MS

Treatment and study plan

Primary outcomes

  1. Time to First Clinical Inflammatory Relapse

    Time frame: Up to 12 months

    Compare the time to first clinical inflammatory relapse between two groups of patients who developed relapsing-remitting MS (RRMS) after age 50:

    • Group 1 = therapeutic escalation strategy: starting with a moderately effective treatment (teriflunomide, dimethyl fumarate or diroximel fumarate, glatiramer acetate, interferon beta, peginterferon)
    • Group 2 = induction strategy: starting with a highly effective treatment (fingolimod, ponesimod, natalizumab, rituximab, ocrelizumab, ofatumumab, cladribine)

Study contacts

Contact information is provided by the study sponsor or research team.

Nicolas Collongues, MD

CONTACT

[email protected]

33 3.88.12.87.33

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Registry information

Acronym: 50-CENT

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jan 2, 2026
Registry last updated
Jan 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.